• Explore /
  • Poster
  • / Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.

Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.

Abstract Poster

Authors

Josep Tabernero

Josep Tabernero

Vall d’Hebron University Hospital and Institute of Oncology (VIHO), Barcelona, Spain

Josep Tabernero , Yung-Jue Bang , Eric Van Cutsem , Charles S. Fuchs , Yelena Y. Janjigian , Pooja Bhagia , Kan Li , David E. Adelberg , Shu Kui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03675737

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS263)

DOI

10.1200/JCO.2021.39.3_suppl.TPS263

Abstract #

TPS263

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Rui-hua Xu

First Author: Sun Young Rha

First Author: Hendrik-Tobias Arkenau

First Author: Manish A. Shah